Yasin H, Mathews M, Suh J and Finkel D. Acute Kidney Injury Associated with Sofosbuvir-Simeprevir in a Patient with Chronic Hepatitis C Virus Infection and HIV Infection: A Case Report.
. 2017; 5(12):298-300. doi: 10.12691/AJMCR-5-12-4
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Lawitz, Eric, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky et al. “Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST‐2).” Hepatology (2015). |
|
[2] | Chopp, S., Vanderwall, R., HUIT, A., & Klepser, M. (2015). Simeprevir and sofosbuvir for treatment of hepatitis C infection. American Journal of Health-System Pharmacy, 72(17). |
|
[3] | Bunchorntavakul, C., & Tanwandee, T. (2015). Treatment of Chronic Hepatitis C in Special Populations. Gastroenterology Clinics of North America, 44(4), 883-900. |
|
[4] | Saab, S., Greenberg, A., Li, E., Bau, S. N., Durazo, F., El‐Kabany, M., ... & Busuttil, R. W. (2015). Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver International, 35(11), 2442-2447. |
|
[5] | Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., ... & Rustgi, V. (2014). Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine, 370(20), 1879-1888. |
|
[6] | Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales Jr, F. L., ... & Craxi, A. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347(13), 975-982. |
|
[7] | Aqel, B. A., Pungpapong, S., Leise, M., Werner, K., Chervenak, A. E., Watt, K. D., ... & Vargas, H. E. (2015). Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology, 62(4), 1004-1012. |
|
[8] | Butt, A. A., Yan, P., Shaikh, O. S., Chung, R. T., & Sherman, K. E. (2015). Sofosbuvir‐based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver International. |
|
[9] | Wanchoo, R., Thakkar, J., Schwartz, D., & Jhaveri, K. D. (2016). Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury. The American journal of gastroenterology, 111(1), 148. |
|
[10] | Maruyama, A., Partovi, N., Yoshida, E. M., Erb, S. R., Azalgara, V. M., & Hussaini, T. (2015). A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrology Dialysis Transplantation, gfv361. |
|
[11] | Burgess, S., Partovi, N., Yoshida, E. M., Erb, S. R., Azalgara, V. M., & Hussaini, T. (2015). A Review of Drug Interactions With Direct-Acting Antivirals for Hepatitis C Implications for HIV and Transplant Patients. Annals of Pharmacotherapy, 1060028015576180. |
|
[12] | Sofosbuvir full prescribing information. (n.d.). Retrieved from http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf |
|
[13] | simeprevir full prescribing information. (n.d.). Retrieved from http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. |
|
[14] | Fontaine, Hélène, et al. “Bradyarrhythmias Associated with Sofosbuvir Treatment.” N Engl J Med 373.19 (2015): 1886-8. |
|
[15] | Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., ... & Schwartz, H. (2014). Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine, 370(3), 211-221. |
|
[16] | Jacobson, Ira M., et al. “SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study.” Hepatology 58.Suppl 1 (2013): 1379A. |
|
[17] | Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., ... & Membreno, F. E. (2014). Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. The Lancet, 383(9916), 515-523. |
|
[18] | Osinusi, A., Meissner, E. G., Lee, Y. J., Bon, D., Heytens, L., Nelson, A., ... & Herrmann, E. (2013). Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.Jama, 310(8), 804-811. |
|
[19] | Nazario, H. E., Ndungu, M., & Modi, A. A. (2015). Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR< 30 ml/min. Liver International. |
|
[20] | Hundemer, G. L., Sise, M. E., Wisocky, J., Ufere, N., Friedman, L. S., Corey, K. E., & Chung, R. T. (2015). Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infectious Diseases, 47(12), 924-929. |
|
[21] | Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., ... & Terrault, N. A. (2016). Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function. Liver International. |
|
[22] | Rokx, C., Alshangi, H., Verbon, A., Zietse, R., Hoorn, E. J., & Rijnders, B. J. (2015). Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.Journal of Infectious Diseases, jiv466. |
|
[23] | Jin, S., Kim, M. H., Park, J. H., Jung, H. J., Lee, H. J., Kim, S. W., ... & Chang, H. H. (2015). The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens. Infection & chemotherapy, 47(4), 239-246. |
|